LHC Group, Inc. (NASDAQ:LHCG) CEO Keith G. Myers sold 75,000 shares of the company’s stock in a transaction on Wednesday, January 9th. The shares were sold at an average price of $95.07, for a total value of $7,130,250.00. Following the completion of the sale, the chief executive officer now owns 155,475 shares in the company, valued at $14,781,008.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ LHCG opened at $97.61 on Friday. LHC Group, Inc. has a twelve month low of $58.65 and a twelve month high of $107.51. The stock has a market cap of $3.01 billion, a P/E ratio of 40.22, a price-to-earnings-growth ratio of 1.36 and a beta of 0.88. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.17.
LHC Group (NASDAQ:LHCG) last released its earnings results on Wednesday, October 31st. The health services provider reported $0.95 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.95. LHC Group had a return on equity of 8.23% and a net margin of 3.85%. The firm had revenue of $507.00 million for the quarter, compared to the consensus estimate of $515.03 million. During the same period in the prior year, the business posted $0.64 earnings per share. The firm’s revenue for the quarter was up 88.0% compared to the same quarter last year. On average, equities analysts anticipate that LHC Group, Inc. will post 3.53 EPS for the current year.
Several brokerages have recently issued reports on LHCG. Zacks Investment Research upgraded LHC Group from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a research report on Wednesday, January 2nd. Barclays began coverage on LHC Group in a research report on Friday, December 14th. They issued an “equal weight” rating and a $105.00 price objective on the stock. UBS Group began coverage on LHC Group in a research report on Thursday, November 15th. They issued a “buy” rating and a $109.00 price objective on the stock. Robert W. Baird upped their price objective on LHC Group from $95.00 to $98.00 and gave the company a “neutral” rating in a research report on Friday, November 2nd. Finally, William Blair restated a “buy” rating on shares of LHC Group in a research report on Thursday, November 1st. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. LHC Group currently has a consensus rating of “Buy” and an average target price of $105.77.
ILLEGAL ACTIVITY WARNING: This news story was originally published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/01/12/lhc-group-inc-lhcg-ceo-sells-7130250-00-in-stock.html.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Further Reading: What is a Derivative?
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.